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Dear Sir,
We read with interest the article by Dauby et al. which
highlighted an approximately 5-fold increase compared
with HIV-infected individuls born before 1970 in the risk
of measles seronegativity in HIV-infected subjects born
after 1970 [1].
In recent years, there has been a substantial increase in
the number of measles cases reported in Italy, as in other
European Union/European Economic Area (EU/EEA)
countries, as a consequence of a reduction in vaccine
coverage in children, with ongoing risk of community-
wide transmission. From 1 January to 31 May 2018,
1258 measles cases and four measles-associated deaths
were reported to the National Institute of Health in Italy.
The median age for the cases was 25 years and 90% were
not vaccinated at the time of infection [2].
Epidemic measles circulation represents a risk for
immunodepressed subjects. It has been shown that coin-
fection with HIV and measles more than doubles the odds
of death in children with measles. Clinical presentation of
measles in HIV-infected adults is frequently atypical and
the diagnosis is difficult. In the few cases described, all
patients had known HIV infection at the time of measles
diagnosis [3,4]. However, if HIV infection is unknown,
the diagnosis of measles can be delayed.
Recently, a 29-year-old Sicilian man with unknown
HIV infection who had not been vaccinated against
measles was admitted to our Infectious Diseases Unit. He
had no relevant medical history and had had a high fever
(39.5°C), dysphagia, haematuria, cough and respiratory
distress for 5 days.
Clinical findings on admission were a high pulse and
respiratory rate, oral candidiasis, leukopaenia (3.4 9 109
cells/L) with lymphopaenia (0.6 9 109 cells/L), mild ele-
vation of inflammatory markers, and bilateral diffuse
interstitial infiltrates on chest radiography. Blood and
urine cultures and serology for Legionella spp.,
Mycoplasma pneumoniae and Chlamydia pneumoniae
were negative. Sputum samples were repeatedly negative
for bacteria, mycobacteria and fungi. An interferon-
gamma release assay test was negative. Empiric treatment
with piperacillin/tazobactam and levofloxacin plus O2
therapy was started.
When HIV infection was confirmed (CD4 cell count
130 cells/lL; HIV viral load 1 500 000 HIV-1 RNA
copies/ml), antiretroviral therapy with dolutegravir and
tenofovir/emtricitabine was started. Intravenous trimetho-
prim-sulfamethoxazole (TMP/SMX) was administered on
the basis of hypothesized Pneumocystis jirovecii infection.
On day 4, rare maculopapular elements appeared in the
upper part of the chest, and high fever and haematuria
persisted. An allergic reaction was suspected and TMP/
SMX was discontinued. Respiratory distress worsened;
chest radiography revealed the progression of bilateral
diffuse interstitial and alveolar infiltrates. Serology for
measles was performed and the sample tested positive for
specific immunoglobulin M (IgM) and negative for
immunoglobulin G (IgG) antibodies. Measles virus was
detected by polymerase chain reaction in the patient’s
saliva, urine and blood.
On day 5, because of severe respiratory failure, the
patient was transferred to the intensive care unit, and
mechanical ventilation was started. Cytology of Bronch-
oalveolar Lavage samples showed an acute inflammatory
response with atypical epithelial cells, supporting a diag-
nosis of viral infection. His respiratory condition did not
improve, and after 3 days the patient died. His parents
declined an autopsy.
This case is a further demonstration that measles can be
fatal in adult HIV-infected late-presenter patients. Not
being aware of the severe state of immunodepression
linked to HIV infection made the diagnosis of atypical
measles more difficult; the appearance of exanthema after
the administration of TMP/SMX led us into the error of
thinking that it was an allergic reaction to the antibiotic.
We underscore the need for physicians to consider the
diagnosis of measles in HIV-infected patients with respi-
ratory distress during measles outbreaks. Screening for
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vaccine-preventable diseases is recommended for all HIV-
infected patients and vaccination should be offered to
susceptible patients, with the exception of those with
high-level immunosuppression [5].
References
1 Dauby N, Martin C, Hainaut M et al. Prevalence and risk
factors of measles seronegativity in a cohort of HIV-positive
subjects: a retrospective study. HIV Med 2018; 19: 426–429.
https://doi.org/10.1111/hiv.12610.
2 Italian National Institute of Health. Report N° 42 - June 2018.
http://www.epicentro.iss.it/problemi/morbillo/bollettino.asp.
3 Okamura A, Itakura O, Yoshioka M, Kubota M, Kikuta H,
Kobayashi K. Unusual presentation of measles giant cell
pneumonia in a patient with acquired immunodeficiency
syndrome. Clin Infect Dis 2001; 32: E57–E58.
4 Ross LA, Kim KS, Mason WH Jr, Gomperts E. Successful
treatment of disseminated measles in a patient with
acquired immunodeficiency syndrome: consideration of
antiviral and passive immunotherapy. Am J Med
1990;88:313–314.
5 Rubin LG, Levin MJ, Ljungman P et al. Infectious Diseases
Society of America. 2013 IDSA clinical practice guideline for
vaccination of the immunocompromised host. CID
2014;58:309–318.
© 2019 British HIV Association HIV Medicine (2019), 20, 6--7
Letter to the Editor e7
